Noble Financial Maintains 'Buy' Rating on Galena (GALE); NeuVax Enrollment Nearly Complete
Tweet Send to a Friend
Noble Financial affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $5 following Q4 results and update ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
